(Q44526163)

3 December 2017

Rescue of mutant p53 transcription function by ellipticine (English)

1 reference

3 December 2017

Yanhua Peng

1

1 reference

3 December 2017

Changgong Li

2

1 reference

3 December 2017

Lihong Chen

3

1 reference

3 December 2017

Said Sebti

4

1 reference

3 December 2017

Jiandong Chen

5

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

22

1 reference

3 December 2017

4478-4487

1 reference

3 December 2017

29

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206777

3 December 2017

0 references

cites work

A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

c-Myc target gene specificity is determined by a post-DNAbinding mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Correcting temperature-sensitive protein folding defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Elliptinium acetate in metastatic breast cancer--a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Mdm2 promotes the rapid degradation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Regulation of p53 stability by Mdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Activation of an MDM2-specific caspase by p53 in the absence of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Temperature-sensitive mutants of p53 homologs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Phase II study of elliptinium acetate salvage treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

The p53-mdm-2 autoregulatory feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

Pharmacological rescue of mutant p53 conformation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206777

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1206777

1 reference

3 December 2017

1 reference